Adr ratio change

September 19, 2024 biodexa pharmaceuticals plc (“biodexa” or the “company”) adr ratio change biodexa pharmaceuticals plc (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its american depositary receipts (“adr”) from one (1) adr representing four hundred (400) ordinary shares, to the new ratio of one (1) adr representing ten thousand (10,000) ordinary shares (the "ratio change"). the effective date of the ratio change is expected to be october 4,2024.
BDRX Ratings Summary
BDRX Quant Ranking